Preclinical, Clinical, Anecdote: Ranking Peptide Evidence

From weakest to strongest: mechanistic speculation; in vitro work in cells; animal studies; small uncontrolled human studies; randomised controlled trials; systematic reviews and meta-analyses of good trials.

Most peptide ingredients sold as supplements sit in the first three tiers. That is not damning — everything starts there — but it is the honest description, and it is rarely how the marketing reads.

In vitro work applies a compound directly to cells at a chosen concentration. It bypasses digestion, absorption, distribution, metabolism and excretion entirely.

Concentrations used are often far above anything achievable in a human taking an oral dose. Showing an effect in a dish establishes that an effect is possible under those conditions; it does not establish that it happens in you.

Three things decide whether an animal study supports a consumer claim. Species: rodent physiology differs meaningfully from human, particularly in metabolism. Route: an intraperitoneal injection in a rat says little about an oral capsule in a person. Dose: check whether the body-weight-scaled dose is anywhere near the product's.

A study using injected doses in rats, cited to support an oral human supplement, is being used as decoration. This is extremely common and it is easy to check — the abstract usually states route and dose.

Citing a study about a different compound in the same family. Citing a study on a different route. Citing the introduction of a paper rather than its findings. Citing a review that itself cites only preclinical work. Listing twenty references where two are relevant and the rest pad the count.

The counter is boring and effective: open one or two citations and read the abstract. Compare species, route and dose against the product. Mismatches show up immediately.

A brand describing an ingredient as studied in preclinical models, with human evidence still limited, is being accurate and is more trustworthy for it.

Confidence beyond the evidence is the signal to watch. The strength of the claim should match the strength of the data, and where it does not, the gap is being filled with something other than research.